IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA

Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E145-50. doi: 10.1152/ajpendo.00085.2006. Epub 2006 Aug 22.

Abstract

Myofibrillar protein loss occurring in catabolic situations is considered to be mediated by the release of proinflammatory cytokines and associated with a decrease in circulating and muscle levels of insulin-like growth factor I (IGF-I). In this paper, we investigated whether the C(2)C(12) myotube atrophy caused in vitro by TNF-alpha/IFN-gamma cytokines might be reversed by exogenous IGF-I. Our results showed that, despite the presence of TNF-alpha/IFN-gamma, IGF-I retained its full ability to induce the phosphorylation of Akt, Foxo3a, and GSK-3beta (respectively, 16-fold, 9-fold, and 2-fold) together with a decrease in atrogin-1 mRNA (-39%, P < 0.001). Although this ubiquitin ligase has been reported to accelerate the degradation of MyoD, a myogenic transcription factor driving the transcription of myosin heavy chain (MHC), IGF-I failed to blunt the reduction of MyoD and MHC caused by TNF-alpha/IFN-gamma. Moreover, IGF-I only very slightly attenuated the myotube atrophy induced by TNF-alpha/IFN-gamma (TNF-alpha/IFN-gamma 15.48 mum alone vs. TNF-alpha/IFN-gamma/IGF-I 16.97 mum, P < 0.001). In conclusion, our data show that IGF-I does not reverse the myotube atrophy induced by TNF-alpha/IFN-gamma despite the phosphorylation of Foxo and GSK-3beta and the downregulation of atrogin-1 mRNA. Our study suggests therefore that factors other than IGF-I decrease are responsible for the muscle atrophy caused by proinflammatory cytokines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Cytokines / adverse effects*
  • Forkhead Box Protein O3
  • Forkhead Transcription Factors / metabolism*
  • Glycogen Synthase Kinase 3 / metabolism*
  • Glycogen Synthase Kinase 3 beta
  • Inflammation Mediators / adverse effects*
  • Insulin-Like Growth Factor I / pharmacology*
  • Interferon-gamma / pharmacology
  • Mice
  • Muscle Fibers, Skeletal / drug effects
  • Muscle Proteins / antagonists & inhibitors*
  • Muscle Proteins / metabolism
  • Muscular Atrophy / etiology
  • Muscular Atrophy / prevention & control*
  • MyoD Protein / metabolism
  • Myosin Heavy Chains / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism*
  • SKP Cullin F-Box Protein Ligases / antagonists & inhibitors*
  • SKP Cullin F-Box Protein Ligases / metabolism
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Cytokines
  • Forkhead Box Protein O3
  • Forkhead Transcription Factors
  • FoxO3 protein, mouse
  • Inflammation Mediators
  • Muscle Proteins
  • MyoD Protein
  • MyoD1 myogenic differentiation protein
  • Tumor Necrosis Factor-alpha
  • Insulin-Like Growth Factor I
  • Interferon-gamma
  • Fbxo32 protein, mouse
  • SKP Cullin F-Box Protein Ligases
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Proto-Oncogene Proteins c-akt
  • Glycogen Synthase Kinase 3
  • Myosin Heavy Chains